Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV
- PMID: 32285293
- PMCID: PMC7152693
- DOI: 10.1007/s10096-020-03883-y
Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV
Abstract
Since December 2019, the infection of the new coronavirus (COVID-19) caused an outbreak of new coronavirus pneumonia in Wuhan, China, and caused great public concern. Both COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through ACE2. An in-depth understanding of ACE2 and a series of physiological and physiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical phenomena and then deal with them timely. In addition, ACE2 is a potential therapeutic target. This article will summarize the role of ACE2 in multiple organ damage caused by COVID-19 and SARS-CoV, targeted blocking drugs against ACE2, and drugs that inhibit inflammation in order to provide the basis for subsequent related research, diagnosis and treatment, and drug development.
Keywords: Angiotensin-converting enzyme 2 (ACE2); New coronavirus (COVID-19); SARS coronavirus (SARS-CoV).
Similar articles
-
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002/jmv.25785. Epub 2020 Apr 5. J Med Virol. 2020. PMID: 32221983 Free PMC article. Review.
-
Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).Ann Clin Biochem. 2020 Sep;57(5):339-350. doi: 10.1177/0004563220928361. Epub 2020 Jun 2. Ann Clin Biochem. 2020. PMID: 32369402 Free PMC article. Review.
-
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10. J Pathol. 2020. PMID: 32418199 Free PMC article. Review.
-
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.Theranostics. 2020 Jun 12;10(16):7448-7464. doi: 10.7150/thno.48076. eCollection 2020. Theranostics. 2020. PMID: 32642005 Free PMC article. Review.
-
Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications.Hypertension. 2020 Nov;76(5):1339-1349. doi: 10.1161/HYPERTENSIONAHA.120.15256. Epub 2020 Aug 27. Hypertension. 2020. PMID: 32851855 Free PMC article. Review.
Cited by
-
The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease.Neurosci Insights. 2020 Nov 22;15:2633105520975743. doi: 10.1177/2633105520975743. eCollection 2020. Neurosci Insights. 2020. PMID: 33283188 Free PMC article. Review.
-
COVID-19 PICU guidelines: for high- and limited-resource settings.Pediatr Res. 2020 Nov;88(5):705-716. doi: 10.1038/s41390-020-1053-9. Epub 2020 Jul 7. Pediatr Res. 2020. PMID: 32634818 Free PMC article.
-
Lymphocyte count is a universal predictor of health outcomes in COVID-19 patients before mass vaccination: A meta-analytical study.J Glob Health. 2022 Sep 17;12:05041. doi: 10.7189/jogh.12.05041. J Glob Health. 2022. PMID: 36112520 Free PMC article.
-
An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment.Eur J Pharmacol. 2020 Nov 5;886:173457. doi: 10.1016/j.ejphar.2020.173457. Epub 2020 Aug 1. Eur J Pharmacol. 2020. PMID: 32750366 Free PMC article. Review.
-
A five-step risk management process for geriatric dental practice during SARS-CoV-2 pandemic.Gerodontology. 2021 Mar;38(1):17-26. doi: 10.1111/ger.12499. Epub 2020 Sep 25. Gerodontology. 2021. PMID: 32978832 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous